SiteRite™ 9 Ultrasound System Delivers Enhanced Image Quality and Vessel Assessment Tools to Aid in First Attempt IV Insertion Success FRANKLIN LAKES, N.J., Nov. 30, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today launched a new, advanced ultrasound system designed to help improve clinician efficiency when placing peripherally inserted central catheters (PICCs), central venous catheters, IV lines and other vascular access devices..

SiteRite™9超声系统提供增强的图像质量和血管评估工具，以帮助首次尝试IV插入成功新泽西州富兰克林湖，2023年11月30日/PRNewswire/-BD（Becton，Dickinson and Company）（纽约证券交易所：BDX），一家领先的全球医疗技术公司，今天推出了一款新的，先进的超声系统旨在帮助提高临床医生在放置外周插入的中心导管（PICC），中心静脉导管，IV线和其他血管通路装置时的效率。。

Continue Reading

继续阅读

BD launches SiteRite™ 9 Ultrasound System, a new, advanced ultrasound system designed to help improve clinician efficiency when placing peripherally inserted central catheters (PICCs), central venous catheters, IV lines and other vascular access devices.

BD启动SiteRite™9超声系统，一种新的先进超声系统，旨在帮助提高临床医生在放置外周插入的中心导管（PICC），中心静脉导管，IV线和其他血管通路装置时的效率。

The SiteRite™ 9 Ultrasound System is an all-in-one system designed with a user-friendly experience on an updated 15.6-inch touch screen with enhanced image quality that provides industry-leading catheter placement tools and technologies to support clinicians during the vascular access device insertion process.

SiteRite™9超声系统是一款一体化系统，在更新的15.6英寸触摸屏上提供用户友好的体验，提高图像质量，为血管通路装置插入过程中的临床医生提供行业领先的导管放置工具和技术。

The system includes integrated visualization tools such as the Cue™ Needle Tracking System to provide nurses with continuous and real-time needle tracking, and the Sherlock 3CG+™ Tip Confirmation System to ensure proper catheter tip navigation and location..

该系统包括集成的可视化工具，如Cue™针跟踪系统为护士提供连续和实时的针跟踪，以及Sherlock 3CG+™尖端确认系统，以确保正确的导管尖端导航和位置。。

'Our latest innovation in ultrasound technology is designed to make vascular access care delivery easier and more efficient for clinicians — whether they've been on the job for years or are new to the field,' said Eric Borin, worldwide president of Medication Delivery Solutions at BD. 'By combining our decades of leadership in vascular access with voice-of-the-customer enhancements, we've developed a best-in-class solution to aid in insertion success on the first attempt and reduce the need for repeated needlesticks to deliver a better care experience for everyone involved.'.

全球药物输送解决方案总裁埃里克·鲍林（Eric Borin）说：“我们最新的超声技术创新旨在使临床医生更容易，更有效地提供血管通路护理服务-无论他们工作多年还是新领域。”通过将我们数十年的血管通路领导力与客户增强的声音相结合，我们开发了一流的解决方案，以帮助首次尝试插入成功，并减少重复针刺的需要，为所有相关人员提供更好的护理体验。

SiteRite™ 9 also features smart, connected technology such as vessel assessment tools that automatically detect the vessel, then pair with vessel measurement tools to help clinicians select the appropriate catheter, so they can make an informed decision every time. Additional system capabilities include patient data look up with information capture, auto-filling capabilities and records transfer to help support clinician workflow.As a global leader in vascular access solutions, BD is committed to advancing the standard of care for patients and health care providers.

SiteRite™9还具有智能连接技术，如血管评估工具，可自动检测血管，然后与血管测量工具配对，帮助临床医生选择合适的导管，以便他们每次都能做出明智的决定。其他系统功能包括患者数据查找以及信息采集，自动填充功能和记录传输，以帮助支持临床医生的工作流程。作为血管通路解决方案的全球领导者，BD致力于推进患者和医疗保健提供者的护理标准。

This innovation is part of the company's vascular access management portfolio and further drives the company's 'One-Stick Hospital Stay' vision by helping clinicians in performing one of the most common invasive hospital procedures — placing a vascular access device — by using ultrasound technology to increase first attempt insertion success and reduce unnecessary needlesticks.

这项创新是公司血管通路管理组合的一部分，并通过使用超声技术帮助临床医生执行最常见的侵入性医院程序之一-放置血管通路装置-来进一步推动公司的“一键住院”愿景。首先尝试插入成功并减少不必要的针刺。

SiteRite™ 9 received 510(k) clearance in September and is now commercially available to customers in the U.S. For more information, visit bd.com/SiteRite9.About BDBD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care.

SiteRite™9月获得510（k）许可，现已在美国客户处商业化。有关更多信息，请访问bd.com/SiteRite9.About BDBD是世界上最大的全球医疗技术公司之一，正在通过改善医疗发现，诊断和提供护理来推进健康世界。

The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation o.

该公司通过开发创新技术，服务和解决方案来支持医疗保健前线的英雄，这些技术，服务和解决方案有助于推进患者的临床治疗和医疗保健提供者的临床过程。BD及其70000多名员工热衷于并致力于帮助提高临床医生护理服务流程的安全性和效率，使实验室科学家能够准确检测疾病并提高研究人员开发下一代o的能力。

Contacts:

联络：

Media:

媒体：

Investors:

投资者：

Alyssa Kretlow

Alyssa Kretlow

Greg Rodetis

Greg Rodetis

BD Corporate Communications

BD公司通讯

BD Investor Relations

BD投资者关系

551.238.4391

551.238.4391

201.847.6875

201.847.6875

[email protected]

[电子邮件保护]

[email protected]

[电子邮件保护]

SOURCE BD (Becton, Dickinson and Company)

来源BD（Becton，Dickinson and Company）